论文部分内容阅读
作者对1985年12月到1989年3月诊断明确的77名CML进行了细胞遗传学与临床分期及预后研究。细胞遗传学分析是直接取骨髓或外周血细胞或外周细胞和骨髓细胞在无刺激下培养1～3天进行的,细胞中期分裂的染色体用常规胰蛋白酶-Giemsa分带技术和根据ISCN来判断核型。用3种限制酶BglⅡ,BamHT,Hind Ⅲ和bcr-1,phl/bcr-3探针来探测bcr重排。 70/77例(91％)骨髓或外周血细胞Ph′(+),64/70例有标准t(9;22)(q~(34);q~(11)),6例有易位变异。55例慢性期中有2例,11例加速期有6例,23例急变期有18例除有Ph′还有其他染色体畸变,常见为双Ph′,+8,+19和+21,其发生率分别为43％、38％、29％和24％。6/7例Ph′(-)病人慢性期核型正常,1/7例显
The authors conducted a cytogenetic and clinical staging and prognostic study of 77 CML patients diagnosed between December 1985 and March 1989. Cytogenetic analysis is performed directly on bone marrow or peripheral blood cells or peripheral and bone marrow cells cultured for 1-3 days without stimulation. Chromosomes of metaphase cells are analyzed by conventional trypsin-Giemsa banding techniques and karyotypes based on ISCN . The bcr rearrangements were probed with three restriction enzymes BglII, BamHT, HindIII and bcr-1, phl / bcr-3 probes. There were 70 cases (91%) of bone marrow or peripheral blood cells Ph ’(+), 64/70 cases had standard t (9; 22) (q ~ (34); q ~ (11) . There were 2 cases in the 55 cases of chronic phase, 6 cases in 11 cases and 18 cases in 23 cases of blastic phase, except for Ph ’and other chromosomal aberrations, which were commonly found to be Ph’, +8, +19 and +21 Rates were 43%, 38%, 29% and 24% respectively. 6/7 cases of Ph ’(-) patients with normal chronic karyotype, 1/7 cases were significant